Lottie file
Innovatie
ELaiGIBLE
Opschaling
AI-powered matching of patients to clinical trials.
ELaiGIBLE securely connects to Electronic Health Record (EHR/EPD) systems and can automatically identify eligible patients that meet the inclusion and exclusion criteria of clinical trials running at hospitals, with 90%+ matching accuracy in a matter of minutes.
AI
Digitalisering
Informatie-uitwisseling
Regio Zuid-Holland
Help ons versnellen
We look for Principal Investigators, Heads of Clinical Departments, and Innovation Managers who are looking to reduce administration tasks for their healthcare professionals.
Our disease focus areas currently are: Cardiovascular and metabolic, Alzheimer's, Dementia and Parkinson
Nima Salami
Probleemstelling
Hospitals & doctors have no overview of their patients’ eligibility for clinical trials running at their sites, because 80% of clinical data is unstructured and unreadable by existing tools.
85% of all trials worldwide are cancelled or delayed due to recruitment problem: Not finding eligible patients fast enough.
2/3rd of trial sites fail to meet the original patient recruitment targets and timeline.
This leads to delays that cost pharmaceutical companies up to $8 Million a day.
Oplossing
A software platform that helps doctors identify and pre-screen more patients, faster and more conveniently, which speeds up the process from months to minutes. All powered by a unique combination of AI & Privacy technologies.
ELaiGIBLE is a high-precision AI clinical trial matching tool that can process all data types from Health Information Systems, helping hospitals speed up the pre-screening process from months to near real-time by reducing manual data validation, and identifying more eligible patients that would otherwise miss the opportunity to receive new treatments.
VWS-missies
OASYS NOW can contribute to several VWS missions:
- Improved health outcomes and reduced disparities: By accelerating clinical trials and improving patient identification, we can contribute to the development of new treatments and reduce health inequalities.
- Reduced burden of chronic diseases: By facilitating the development of new medicines and treatments for chronic diseases, we can help reduce their impact on individuals and society.
- Increased participation of people with chronic illnesses: By improving access to new medicines and clinical trials, we can empower patients with chronic diseases to manage their health and participate more fully in society.
- Improved quality of life for people with dementia: By facilitating clinical trials for dementia treatments, we can contribute to improving the quality of life for patients and their caregivers.
Our mission to make personalized healthcare and precision medicine accessible and equitable aligns with these goals, and our platform has the potential to make a significant contribution to achieving them.
Doelgroep
OASYS NOW's target audience is primarily pharmaceutical companies, clinical research organizations (CROs), and academic Medical Centers and Top Clinical Hospitals (STZ) conducting clinical trials. The global clinical trial market size was valued at approximately $47.0 billion in 2021 and is estimated to reach $73.2 billion by 2030.
Within this market, there is a growing need for innovative solutions to improve the efficiency and effectiveness of patient recruitment. This is evidenced by the fact that 80% of clinical trials fail to meet their original patient enrollment deadlines and up to 50% of research sites enroll one or no patients in a given trial.
By addressing these challenges, OASYS NOW aims to serve a significant portion of the clinical trial market, particularly those focused on rare and chronic diseases where patient recruitment is particularly difficult.
Verlaging zorgkosten
OASYS NOW contributes to a reduction in healthcare costs in several ways:
Reduced clinical trial costs: By accelerating patient recruitment, our platform can significantly reduce the overall cost of clinical trials. This is because patient recruitment is one of the most time-consuming and expensive aspects of clinical trials, often accounting for up to 30% of the total budget.
Faster time-to-market for new medicines: By speeding up clinical trials, our platform can help bring new medicines to market faster. This can lead to lower healthcare costs by providing patients with access to more effective treatments earlier.
Improved patient outcomes: By improving the accuracy of patient identification and ensuring that patients are matched to the most appropriate clinical trials, our platform can help improve patient outcomes. This can lead to lower healthcare costs by reducing the need for additional treatments or hospitalizations.
Reduced administrative burden: Our platform can reduce the administrative burden on healthcare professionals by automating many of the tasks associated with patient recruitment and screening. This can free up their time to focus on patient care, which can lead to improved efficiency and lower healthcare costs.
Overall, OASYS NOW's innovative platform has the potential to make a significant contribution to reducing healthcare costs by streamlining clinical trials, accelerating time-to-market for new medicines, improving patient outcomes, and reducing administrative burden.
Verdienmodel
OASYS NOW operates on a flexible, value-driven business model with two main components:
Subscription Model: We offer our software as a service (SaaS), providing access to our platform through a subscription model. The cost is tailored to the specific needs of each client, considering factors like the number of users, trials managed, and support required.
Success Fee Model: To further align our success with our clients', we also offer a performance-based option. This includes a lower-cost SaaS subscription combined with a success fee for each eligible patient we identify and help recruit into a trial.
This dual approach allows us to cater to various client needs and budgets while incentivizing performance and shared success. It ensures OASYS NOW remains committed to delivering exceptional value and contributing to the efficiency and effectiveness of clinical trials.
Geïnvesteerd vermogen
€ 100 duizend-1miljoen
Concurrentie
OASYS NOW's biggest competitors are traditional patient recruitment methods and other technology-driven solutions in the clinical trial patient recruitment market. These include:
Traditional methods: Manual patient identification through physician referrals, patient registries, and advertising. These methods are often time-consuming, inefficient, and costly.
Other technology solutions: Existing patient recruitment platforms and software that may offer some automation but lack the advanced AI and real-world data capabilities of OASYS NOW.
Currently, without our innovation, the process of recruiting patients for clinical trials is often slow, expensive, and inaccurate. This leads to delays in bringing new medicines to market and can result in increased healthcare costs.
OASYS NOW's innovation reduces healthcare costs by:
Accelerating patient recruitment: This can significantly reduce the overall cost of clinical trials, as patient recruitment is one of the most time-consuming and expensive aspects.
Improving patient identification accuracy: This ensures that patients are matched to the most appropriate clinical trials, which can lead to improved patient outcomes and lower healthcare costs by reducing the need for additional treatments or hospitalizations.
Reducing administrative burden: This can free up healthcare professionals' time to focus on patient care, improving efficiency and potentially lowering healthcare costs.
Unieke kenmerken
OASYS NOW is innovative in several ways:
AI-powered patient identification: Our platform uses advanced AI algorithms to analyze electronic health records and automatically identify eligible patients for clinical trials. This is a significant improvement over traditional methods, which are often manual and time-consuming.
Real-world data integration: We leverage real-world data (RWD / EHR) to provide a more comprehensive view of patients' health status and eligibility for clinical trials. This allows us to identify patients who may be missed by traditional recruitment methods.
Patient empowerment: Our platform empowers patients with access to their health data and treatment options via an app. This allows them to be more proactive in managing their health and make informed decisions about participating in clinical trials.
Focus on rare and chronic diseases: We are particularly focused on helping to accelerate clinical trials for rare and chronic diseases, where patient recruitment is especially challenging.
Cybersecurity and data privacy: We are deeply committed to cybersecurity and data privacy, building our platform with a "privacy-by-design" approach. We adhere to all relevant regulations, including GDPR, ISO27001, NE7510, EU AI Act, and other applicable guidelines, to guarantee the highest standards of data protection.
These innovations make OASYS NOW a unique and valuable solution for improving the efficiency and effectiveness of clinical trials, ultimately contributing to the development of new and better treatments for patients.
Intellectueel eigendom
OASYS NOW holds trademarks for our company branding and some of our products and technologies. We are consulting with our IP lawyers about applying for patents for our privacy solutions in the areas of confidential federated learning and secure data integrations.
Organisatie
OASYS NOW's goal is to become one of the largest software companies in Europe specializing in cybersecurity and AI for healthcare and life sciences. We aim to be an independent, neutral third party working closely with governments and industries to enable precision medicine research globally. Our focus will be on ensuring privacy and providing win-win-win solutions for all stakeholders. While the exact size is difficult to predict, we anticipate significant growth in the coming years, driven by the increasing demand for innovative solutions in the healthcare sector.
Beschrijving pilotfase
OASYS NOW is currently running a pilot program at three trial sites in the Netherlands in collaboration with Amsterdam UMC, Isala hospital Zwolle, and Jeroen Bosch hospital in Den Bosch. This pilot program automates the patient pre-screening process using their Copilot, which leverages unstructured patient data and AI to match hundreds of patients to trials.
We have also received confirmation to deploy their product at our first hospital before the end of 2024. In addition to unlocking Electronic Health Records (EHR) data, we are expanding into DNA data access for Life Sciences, having won the European Award for Secure and Safe AI for our Confidential Federated Learning security framework for Genomic Research and Biomarker Discovery implemented at Erasmus MC. Our novel cybersecurity technology has been technically validated by NVIDIA & Google.
Betrokken partners
Yes, OASYS NOW has involved partners from the healthcare field in the development and testing of their solutions.
Amsterdam UMC, Isala hospital Zwolle, and Jeroen Bosch hospital: These hospitals are collaborating with OASYS NOW on their pilot program to automate the patient pre-screening process using their Copilot technology.
Erasmus MC: OASYS NOW implemented their Confidential Federated Learning security framework for Genomic Research and Biomarker Discovery at Erasmus MC.
The involvement of these healthcare partners has been crucial in ensuring that OASYS NOW's solutions are relevant, effective, and meet the needs of the healthcare sector.
Aantal gebruikers pilot
0-10
Onderzoeksresultaten
Via our pilots, we were able to showcase the followings for our technology and products:
1. De-ID: We de-identified/pseudonymised unstructured patient records with 98%+ accuracy.
2. ELaiGIBLE: We pre-screened the eligibility and matched hundreds of patients to trials in matters of minutes using our AI Copilot (instead of the manual work that currently takes hundreds of hours for this cohort size).
3. Confidential Federated Learning: We enabled a secure and federated approach to running genomic research using AI for thousands of genomic data between institutes in a compliant manner.
Implementatiestrategie
OASYS NOW's implementation strategy focuses on close collaboration with healthcare providers and research institutions to integrate their platform into existing clinical trial workflows.
They work directly with hospitals and research centers to implement their Copilot technology, which automates the patient pre-screening process.
This hands-on approach ensures that the platform is effectively integrated into the clinical trial process, allowing healthcare providers to easily identify and recruit eligible patients.
The end-users, primarily healthcare professionals involved in clinical trials, benefit from the platform's ability to streamline patient recruitment, improve accuracy, and reduce administrative burden.
To further streamline integration, OASYS NOW has reached agreements with Electronic Healthcare Records (EHR) providers to directly integrate their technology into the EHR systems used daily by healthcare professionals. This will enable seamless access to the platform and its features, further enhancing efficiency and ease of use.
Reeds in gebruik
Currently in use in 4 locations:
- 3 Trials sites in collaboration with Amsterdam UMC, Isala Zwolle, Jeroen Bosch Ziekenhuis Den Bosch
- Erasmus MC
Behaalde prestaties of gewonnen awards
Winner of the Dutch Data Privacy Award 2024: - https://privacyfirst.nl/en/privacyawards/
Winner of the European Lighthouse on Secure & Safe AI: - https://cispa.de/en/winners-call
Winner of the Erasmus University Challenge Award: - https://www.erasmusmagazine.nl/en/2022/09/19/ethnic-dna-database-and-co…
Winner of Stage Two European Startup Competition in Berlin: - https://www.erasmusmagazine.nl/en/2022/10/28/student-start-up-oasys-now…
Productontwikkeling
BI solutions (Business Intelligence) for the Value-Based Health Care (VBHC) teams at hospitals.
Internationale ambitie
We're starting EU-wide.
We also have connections in the following countries who have shown interest:
- Japan
- South Korea
- US (New York)
Omzet
€ 11-100k